LUPIN

Lupin ; Co Receives 2 Observations in USFDA Inspection • 🏭 USFDA Inspection: U.S. Food and Drug Administration completes inspection at Ankleshwar manufacturing facility (Mar 2–7, 2026). • ⚠️ Form 483 Issued: Inspection closed with Form-483 containing 2 observations. • 📝 Next Step: Company will respond to observations within stipulated timeframe. • 🔬 Compliance Commitment: Lupin reiterates adherence to cGMP standards across facilities. 🟡 Impact: Neutral to Slight Negative Limited observations suggest minor regulatory issues, but resolution will determine any impact on operations.